RSLS Annual Total Long Term Liabilities
$223.00 K
+$223.00 K+100.00%
31 December 2023
Summary:
As of January 23, 2025, RSLS annual total long term liabilities is $223.00 thousand, with the most recent change of +$223.00 thousand (+100.00%) on December 31, 2023. During the last 3 years, it has fallen by -$10.74 million (-97.97%). RSLS annual total long term liabilities is now -97.97% below its all-time high of $11.00 million, reached on December 31, 2008.RSLS Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RSLS Quarterly Long Term Liabilities
$103.00 K
-$54.00 K-34.39%
30 September 2024
Summary:
As of January 23, 2025, RSLS quarterly total long term liabilities is $103.00 thousand, with the most recent change of -$54.00 thousand (-34.39%) on September 30, 2024. Over the past year, it has dropped by -$172.00 thousand (-62.55%). RSLS quarterly long term liabilities is now -99.79% below its all-time high of $48.14 million, reached on September 30, 2019.RSLS Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RSLS Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +100.0% | -62.5% |
| 3 y3 years | -98.0% | -91.0% |
| 5 y5 years | -96.4% | -98.0% |
RSLS Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -66.6% | -89.6% | ||
| 5 y | 5-year | -98.0% | -99.1% | ||
| alltime | all time | -98.0% | -99.8% |
ReShape Lifesciences Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $103.00 K(-34.4%) |
| June 2024 | - | $157.00 K(-11.8%) |
| Mar 2024 | - | $178.00 K(-20.2%) |
| Dec 2023 | $223.00 K(>+9900.0%) | $223.00 K(-18.9%) |
| Sept 2023 | - | $275.00 K(-61.3%) |
| June 2023 | - | $710.00 K(-28.4%) |
| Mar 2023 | - | $992.00 K(>+9900.0%) |
| Dec 2022 | $0.00(-100.0%) | $0.00(0.0%) |
| Sept 2022 | - | $0.00(-100.0%) |
| June 2022 | - | $372.00 K(-24.7%) |
| Mar 2022 | - | $494.00 K(-25.9%) |
| Dec 2021 | $667.00 K(-93.9%) | $667.00 K(-41.6%) |
| Sept 2021 | - | $1.14 M(-17.5%) |
| June 2021 | - | $1.39 M(-17.4%) |
| Mar 2021 | - | $1.68 M(-84.7%) |
| Dec 2020 | $10.97 M(+112.6%) | $10.97 M(+109.3%) |
| Sept 2020 | - | $5.24 M(-7.2%) |
| June 2020 | - | $5.64 M(+8.0%) |
| Mar 2020 | - | $5.23 M(+1.3%) |
| Dec 2019 | $5.16 M(-17.4%) | $5.16 M(-89.3%) |
| Sept 2019 | - | $48.14 M(+165.3%) |
| June 2019 | - | $18.15 M(+159.0%) |
| Mar 2019 | - | $7.01 M(+12.1%) |
| Dec 2018 | $6.25 M(+18.0%) | $6.25 M(+188.0%) |
| Sept 2018 | - | $2.17 M(-19.7%) |
| June 2018 | - | $2.70 M(-30.9%) |
| Mar 2018 | - | $3.91 M(-26.1%) |
| Dec 2017 | $5.29 M(>+9900.0%) | $5.29 M(>+9900.0%) |
| Sept 2017 | - | $2200.00(-69.4%) |
| June 2017 | - | $7200.00(-84.6%) |
| Mar 2017 | - | $46.70 K(+19.4%) |
| Dec 2016 | $39.10 K(-98.9%) | $39.10 K(-97.3%) |
| Sept 2016 | - | $1.45 M(-82.5%) |
| June 2016 | - | $8.29 M(+23.2%) |
| Mar 2016 | - | $6.73 M(+96.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $3.43 M(>+9900.0%) | $3.43 M(-4.5%) |
| Sept 2015 | - | $3.59 M(>+9900.0%) |
| June 2015 | - | $0.00(0.0%) |
| Mar 2015 | - | $0.00(0.0%) |
| Dec 2014 | $0.00(-100.0%) | $0.00(0.0%) |
| Sept 2014 | - | $0.00(-100.0%) |
| June 2014 | - | $932.10 K(-51.0%) |
| Mar 2014 | - | $1.90 M(-33.7%) |
| Dec 2013 | $2.87 M(-57.1%) | $2.87 M(-25.1%) |
| Sept 2013 | - | $3.83 M(-20.0%) |
| June 2013 | - | $4.78 M(-16.6%) |
| Mar 2013 | - | $5.73 M(-14.2%) |
| Dec 2012 | $6.68 M(+132.0%) | $6.68 M(-12.4%) |
| Sept 2012 | - | $7.63 M(-11.1%) |
| June 2012 | - | $8.58 M(+91.7%) |
| Mar 2012 | - | $4.48 M(+55.4%) |
| Dec 2011 | $2.88 M(-42.2%) | $2.88 M(-15.9%) |
| Sept 2011 | - | $3.42 M(-13.4%) |
| June 2011 | - | $3.96 M(-11.7%) |
| Mar 2011 | - | $4.48 M(-10.1%) |
| Dec 2010 | $4.98 M(+14.5%) | $4.98 M(+21.1%) |
| Sept 2010 | - | $4.11 M(-16.4%) |
| June 2010 | - | $4.92 M(+43.9%) |
| Mar 2010 | - | $3.42 M(-21.4%) |
| Dec 2009 | $4.35 M(-60.4%) | $4.35 M(-69.3%) |
| Sept 2009 | - | $14.20 M(-15.7%) |
| June 2009 | - | $16.84 M(+44.8%) |
| Mar 2009 | - | $11.63 M(+5.7%) |
| Dec 2008 | $11.00 M(+82.7%) | $11.00 M(+228.7%) |
| Sept 2008 | - | $3.35 M(-21.5%) |
| June 2008 | - | $4.26 M(-17.3%) |
| Mar 2008 | - | $5.15 M(-14.4%) |
| Dec 2007 | $6.02 M(+145.0%) | $6.02 M(+17.3%) |
| Sept 2007 | - | $5.13 M(+108.9%) |
| Dec 2006 | $2.46 M(-66.6%) | $2.46 M(-66.6%) |
| Dec 2005 | $7.34 M | $7.34 M |
FAQ
- What is ReShape Lifesciences annual total long term liabilities?
- What is the all time high annual total long term liabilities for ReShape Lifesciences?
- What is ReShape Lifesciences annual total long term liabilities year-on-year change?
- What is ReShape Lifesciences quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly long term liabilities year-on-year change?
What is ReShape Lifesciences annual total long term liabilities?
The current annual total long term liabilities of RSLS is $223.00 K
What is the all time high annual total long term liabilities for ReShape Lifesciences?
ReShape Lifesciences all-time high annual total long term liabilities is $11.00 M
What is ReShape Lifesciences annual total long term liabilities year-on-year change?
Over the past year, RSLS annual total long term liabilities has changed by +$223.00 K (+100.00%)
What is ReShape Lifesciences quarterly total long term liabilities?
The current quarterly long term liabilities of RSLS is $103.00 K
What is the all time high quarterly long term liabilities for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly total long term liabilities is $48.14 M
What is ReShape Lifesciences quarterly long term liabilities year-on-year change?
Over the past year, RSLS quarterly total long term liabilities has changed by -$172.00 K (-62.55%)